Legend Biotech Corp(LEGN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,758 of 2,960 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
LEGN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Legend Biotech Corp (LEGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LEGN at 47.8/100 on a 32-signal composite quality model, placing it at rank #1,758 of 2,960 stocks — the bottom half of the AI-ranked universe. LEGN scores in the top quartile across revenue growth (96.5), institutional flow (86.1). Areas of concern include balance sheet strength (12.1) and profitability (13.6), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q3 2025), Legend Biotech Corp reports quarterly revenue of $272.4M, net income of $-39.7M. Top institutional holders of LEGN by reported 13-F value include FMR, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), SUVRETTA CAPITAL MANAGEMENT, based on the most recent SEC filings. LEGN trades on the Nasdaq exchange and files with the SEC under CIK 1801198. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LEGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Legend Biotech Corp directly from SEC EDGAR. Legend Biotech Corp's 13F Pro composite quality score has ranged between 23 and 51 since 2024, currently 47.8 — an improving long-term trajectory across 54 quarterly and live scoring snapshots.
Revenue
Q3 2025
$272.4M
Net Income
Q3 2025
$-39.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Total Assets
+3.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | $627.2M +120.0% | $285.1M +143.7% | $117.0M +70.0% | $68.8M -8.2% | $75.0M |
| Total Assets | $1.73B +3.8% | $1.67B -9.7% | $1.85B +38.9% | $1.33B +18.9% | $1.12B +55.0% | $722.1M |
Get alerted when LEGN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Legend Biotech Corp including:
Top Institutional Holders of LEGN
FMR LLC
$840.2M29,093,899 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$235.0M8,137,638 shSUVRETTA CAPITAL MANAGEMENT, LLC
$204.2M7,070,000 shHillhouse Capital Advisors, Ltd.
$172.8M5,984,550 shBlackRock, Inc.
$136.5M4,726,534 shWESTFIELD CAPITAL MANAGEMENT CO LP
$127.9M4,430,063 shGOLDMAN SACHS GROUP INC
$105.8M3,662,315 shPoint72 Asset Management, L.P.
$88.8M3,076,124 shKynam Capital Management, LP
$86.7M3,001,205 shAssenagon Asset Management S.A.
$55.3M1,915,056 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $840.2M | 29,093,899 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $235.0M | 8,137,638 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | $204.2M | 7,070,000 |
| Hillhouse Capital Advisors, Ltd. | $172.8M | 5,984,550 |
| BlackRock, Inc. | $136.5M | 4,726,534 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $127.9M | 4,430,063 |
| GOLDMAN SACHS GROUP INC | $105.8M | 3,662,315 |
| Point72 Asset Management, L.P. | $88.8M | 3,076,124 |
| Kynam Capital Management, LP | $86.7M | 3,001,205 |
| Assenagon Asset Management S.A. | $55.3M | 1,915,056 |
Companies Similar to LEGN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
CENTENE CORP
ARROWHEAD PHARMACEUTICALS, INC.
INSMED Inc
MiniMed Group, Inc.
Ascendis Pharma A/S
ProQR Therapeutics N.V.
Acadia Healthcare Company, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put LEGN on your watchlist
Track score changes the day Legend Biotech Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is LEGN a good stock to buy?
13F Pro's AI-powered analysis of Legend Biotech Corp (LEGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LEGN are available on the LEGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LEGN is classified as a mid company.
Which hedge funds own LEGN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LEGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Legend Biotech Corp's investment landscape.